OKYO Pharma Ltd SEC filings OKYO
OKYO Pharma Ltd has 311 filings in SEC EDGAR's recent list, going back to Mar 22, 2021. Its latest annual report, Form 20-F, was filed on Jul 20, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Nov 5, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4/A | Filing | Aug 7, 2026 | Jul 21, 2026 |
| 4/A | Filing | Aug 7, 2026 | Jul 22, 2026 |
| 4/A | Filing | Aug 7, 2026 | Jul 21, 2026 |
| 4/A | Filing | Aug 7, 2026 | Jul 21, 2026 |
| 4/A | Filing | Aug 7, 2026 | Jul 20, 2026 |
| 4/A | Filing | Aug 7, 2026 | Jul 21, 2026 |
| 4/A | Filing | Aug 7, 2026 | Jul 27, 2026 |
| 4 | Insider transaction | Jul 29, 2026 | Jul 27, 2026 |
| 3 | Initial insider ownership | Jul 29, 2026 | Mar 18, 2026 |
| 4 | Insider transaction | Jul 23, 2026 | Jul 22, 2026 |
| 4 | Insider transaction | Jul 23, 2026 | Jul 21, 2026 |
| 4 | Insider transaction | Jul 23, 2026 | Jul 21, 2026 |
| 4 | Insider transaction | Jul 23, 2026 | Jul 21, 2026 |
| 4 | Insider transaction | Jul 22, 2026 | Jul 21, 2026 |
| 4 | Insider transaction | Jul 21, 2026 | Jul 20, 2026 |
| 3 | Initial insider ownership | Jun 17, 2026 | Mar 18, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 8, 2026 |
| 3 | Initial insider ownership | Jun 2, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Jun 1, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Jun 1, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 22, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 22, 2026 | Mar 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 18, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 12, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 29, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 5, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 27, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 18, 2025 | — |
| 4 | Insider transaction | Oct 31, 2023 | Oct 23, 2023 |
| 4 | Insider transaction | Sep 28, 2023 | Sep 15, 2023 |
| 4 | Insider transaction | May 20, 2022 | May 19, 2022 |
| 4 | Insider transaction | May 19, 2022 | May 19, 2022 |
| 4 | Insider transaction | May 19, 2022 | May 19, 2022 |
| 4/A | Filing | May 18, 2022 | May 17, 2022 |
| 4 | Insider transaction | May 18, 2022 | May 17, 2022 |
| 3 | Initial insider ownership | May 16, 2022 | May 16, 2022 |
| 3 | Initial insider ownership | May 16, 2022 | May 16, 2022 |
| 3 | Initial insider ownership | May 16, 2022 | May 16, 2022 |
| 3 | Initial insider ownership | May 16, 2022 | May 16, 2022 |
| 3 | Initial insider ownership | May 16, 2022 | May 16, 2022 |
| 3 | Initial insider ownership | May 16, 2022 | May 16, 2022 |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OKYO (Nasdaq)
- Headquarters
- London, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1849296
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.